Should I buy or sell Invivyd stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVVD shares. View IVVD analyst ratings or view top-rated stocks .

What is Invivyd's stock price target for 2024?

3 brokerages have issued 12 month price targets for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they expect the company's stock price to reach $11.33 in the next year. This suggests a possible upside of 392.8% from the stock's current price. View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts .

How have IVVD shares performed in 2024?

Invivyd's stock was trading at $3.94 at the beginning of the year. Since then, IVVD stock has decreased by 41.6% and is now trading at $2.30. View the best growth stocks for 2024 here .

Are investors shorting Invivyd?

Invivyd saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 41.5% from the March 15th total of 1,640,000 shares. Based on an average daily volume of 836,800 shares, the short-interest ratio is currently 2.8 days. Approximately 3.9% of the company's stock are sold short. View Invivyd's Short Interest .

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IVVD earnings forecast .

What ETF holds Invivyd's stock?

Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IVVD

Invivyd (IVVD) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free IVVD Stock Alerts

$2.30

-0.05 (-2.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.26
▼
$2.45
50-Day Range: $2.30
▼
$4.44
52-Week Range: $0.98
▼
$5.20

Volume: 1.06 million shs
Average Volume: 825,306 shs
Market Capitalization: $274.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.33

Get Invivyd alerts:

Invivyd MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 392.8% Upside
$11.33 Price Target
Short Interest: Healthy
3.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.05
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.74) to ($0.14) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

370th out of 911 stocks

Biological Products, Except Diagnostic Industry

51st out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Invivyd has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Invivyd has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.85% of the float of Invivyd has been sold short.
Short Interest Ratio / Days to Cover
Invivyd has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Invivyd has recently increased by 41.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Invivyd does not currently pay a dividend.
Dividend Growth
Invivyd does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVVD.

2.8

News and Social Media Coverage

News Sentiment
Invivyd has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Invivyd this week, compared to 1 article on an average week.
Search Interest
9 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
MarketBeat Follows
6 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Invivyd insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Invivyd are expected to grow in the coming year, from ($0.74) to ($0.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Invivyd is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Invivyd is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Invivyd has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Invivyd Stock (NASDAQ:IVVD)

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IVVD Stock News Headlines

April 15, 2024 | globenewswire.com

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

April 15, 2024 | globenewswire.com

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 13, 2024 | americanbankingnews.com

HC Wainwright Weighs in on Invivyd, Inc.'s Q1 2024 Earnings (NASDAQ:IVVD)

April 12, 2024 | msn.com

Invivyd appoints Jeremy Gowler as interim CEO

April 12, 2024 | markets.businessinsider.com

Invivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering Resigns

April 12, 2024 | globenewswire.com

Invivyd Announces CEO Transition

April 8, 2024 | ca.news.yahoo.com

Canadian farmers demand relief from price on carbon imposed by federal government

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 5, 2024 | finanznachrichten.de

Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

April 4, 2024 | finance.yahoo.com

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

April 4, 2024 | globenewswire.com

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

March 28, 2024 | benzinga.com

Invivyd: Q4 Earnings Insights

March 28, 2024 | investorplace.com

IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023

March 28, 2024 | globenewswire.com

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

March 27, 2024 | msn.com

Morgan Stanley ups Invivyd to overweight, cites FDA EUA decision

March 26, 2024 | markets.businessinsider.com

Maintaining Buy on Invivyd: Pemgarda’s EUA and Market Growth Potential

March 26, 2024 | markets.businessinsider.com

Invivyd’s PEMGARDA: Strong Buy Rating on FDA EUA and Strategic Market Positioning

March 26, 2024 | msn.com

FDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune System

March 23, 2024 | finanznachrichten.de

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

March 22, 2024 | stockhouse.com

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

March 22, 2024 | msn.com

Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug

March 22, 2024 | globenewswire.com

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

March 22, 2024 | globenewswire.com

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

March 18, 2024 | edition.cnn.com

Ligand Pharmaceuticals Incorporated

March 13, 2024 | seekingalpha.com

Piper Sandler upgrades Solid Biosciences to overweight

February 24, 2024 | msn.com

Invivyd (IVVD) Price Target Increased by 76.92% to 7.82

See More Headlines

Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IVVD
CUSIP: N/A
CIK: 1832038
Web: adagiotx.com
Phone: 781-819-0080
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.33
High Stock Price Target: $15.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +392.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-198,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.97%
Return on Assets: -67.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.47
Quick Ratio: 4.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.61 per share
Price / Book: 1.43

Miscellaneous

Outstanding Shares: 119,220,000
Free Float: 96,450,000
Market Cap: $274.21 million
Optionable: Optionable
Beta: 0.63

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David Hering M.B.A. (Age 48)
CEO & Director
Comp: $932.5k
Ms. Jill Andersen J.D. (Age 51)
Chief Legal Officer & Corporate Secretary
Comp: $619.33k
Mr. William E. Duke Jr. (Age 52)
M.B.A., Chief Financial Officer
Mr. Jeremy Gowler (Age 47)
Chief Operating Officer & Chief Commercial Officer
Ms. Stacy Price M.S. (Age 55)
Chief Technology & Manufacturing Officer
Dr. Robert D. Allen Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IVVD Stock Analysis - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVVD shares.
View IVVD analyst ratings or view top-rated stocks.
What is Invivyd's stock price target for 2024?: 3 brokerages have issued 12 month price targets for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they expect the company's stock price to reach $11.33 in the next year. This suggests a possible upside of 392.8% from the stock's current price.
View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts.
How have IVVD shares performed in 2024?: Invivyd's stock was trading at $3.94 at the beginning of the year. Since then, IVVD stock has decreased by 41.6% and is now trading at $2.30.
View the best growth stocks for 2024 here.
Are investors shorting Invivyd?: Invivyd saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 41.5% from the March 15th total of 1,640,000 shares. Based on an average daily volume of 836,800 shares, the short-interest ratio is currently 2.8 days. Approximately 3.9% of the company's stock are sold short.
View Invivyd's Short Interest.

When is Invivyd's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IVVD earnings forecast.
What ETF holds Invivyd's stock?: Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.
How do I buy shares of Invivyd?: Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVVD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Invivyd (IVVD) Stock Price, News & Analysis

Invivyd MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Invivyd Stock (NASDAQ:IVVD)

IVVD Stock Price History

IVVD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IVVD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™